NCT04593277
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study No drug interventions supportive_care Not Available active_not_recruiting NCT05896839
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer treatment 1 / 2 recruiting NCT01989585
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma treatment 1 / 2 active_not_recruiting NCT04314401
National Cancer Institute "Cancer Moonshot Biobank" No drug interventions Not Available Not Available recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT05764395
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors treatment 2 suspended NCT04356729
A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma treatment 2 recruiting NCT04708418
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma treatment 2 suspended NCT04940299
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma treatment 2 active_not_recruiting NCT05967533
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors No drug interventions treatment 1 recruiting NCT03816332
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers treatment 1 active_not_recruiting NCT04462406
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial treatment 2 recruiting NCT03698019
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma treatment 2 active_not_recruiting NCT05136196
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study treatment 2 suspended NCT02650986
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 treatment 1 / 2 active_not_recruiting NCT03677739
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families No drug interventions supportive_care Not Available recruiting NCT04516122
Bone Loss in Melanoma Survivors Receiving Immunotherapy No drug interventions Not Available Not Available active_not_recruiting NCT04375527
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma treatment 2 recruiting NCT03727789
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma No drug interventions treatment 1 terminated NCT04007744
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT04902040
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies treatment 1 / 2 recruiting NCT05039801
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors treatment 1 recruiting NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT02224781
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma treatment 3 active_not_recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT02506153
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery treatment 3 active_not_recruiting NCT03554083
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma treatment 2 recruiting NCT06265285
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program health_services_research 2 recruiting NCT05393713
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study treatment 1 active_not_recruiting NCT06075524
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types No drug interventions Not Available Not Available recruiting NCT04967196
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma treatment 1 active_not_recruiting NCT03819296
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer treatment 1 / 2 recruiting NCT04990726
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors No drug interventions Not Available Not Available recruiting NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT03033576
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma treatment 2 active_not_recruiting NCT04067960
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer No drug interventions screening 0 completed NCT04645680
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study No drug interventions supportive_care 2 active_not_recruiting NCT03865212
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT05907512
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma prevention 2 recruiting